Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
- DOI
- 10.1038/s41523-025-00864-2
- Published
- 2025-12-04
- Container
- npj Breast Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41523-025-00864-2,
title = {Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion},
author = {Neil M. Iyengar and Joyce A. O’Shaughnessy and Heather N. Moore and Erika Hamilton and Komal L. Jhaveri and Cynthia X. Ma and Karen Tedesco and Monali Vasekar and Sarah Donahue and Hope S. Rugo},
year = {2025},
journal = {npj Breast Cancer},
doi = {10.1038/s41523-025-00864-2},
url = {https://doi.org/10.1038/s41523-025-00864-2}
}RIS
TY - JOUR TI - Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion AU - Neil M. Iyengar AU - Joyce A. O’Shaughnessy AU - Heather N. Moore AU - Erika Hamilton AU - Komal L. Jhaveri AU - Cynthia X. Ma AU - Karen Tedesco AU - Monali Vasekar AU - Sarah Donahue AU - Hope S. Rugo PY - 2025 JO - npj Breast Cancer DO - 10.1038/s41523-025-00864-2 UR - https://doi.org/10.1038/s41523-025-00864-2 ER -
APA
Iyengar, N. M., O’Shaughnessy, J. A., Moore, H. N., Hamilton, E., Jhaveri, K. L., Ma, C. X., Tedesco, K., Vasekar, M., Donahue, S., & Rugo, H. S. (2025). Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. npj Breast Cancer. https://doi.org/10.1038/s41523-025-00864-2
Source records
- crossref · retrieved 2026-09-26T11:42:18.931Z